CD8A and metastatic neoplasm: A phase Ib trial in patients with high TMB metastatic tumors demonstrated that personalized neoantigen vaccine plus anti‐PD‐1 induced neoantigen‐specific CD4+ and CD8+ T cell responses, with antitumor capability.54